Howe Jill Ann bought 20,000 shares of Lineage Cell Therapeutics, Inc. at $0.86 for $17.1k on Nov 16, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Chief Financial Officer
Chief Financial Officer
Filed Nov 16, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$17,100Shares × reported price
Shares traded
20,000Common Shares
Price per share
$0.86Reported price. Read footnotes for ranges.
% of reported position traded
78.43%This security and ownership context
Holdings after
45,500Direct
Trade date
Nov 16, 2026Buy
Filed
Nov 16, 2026, 5:00 PM ET0-day reporting delay
Accession
0001193125-26-463787Code P · Transaction 401906
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 25,500 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

LCTX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LCTX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 23, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago 0%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: 1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.84 to $0.94 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within theranges set forth in this footnote 1.